We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

81 hedge funds and large institutions have $701M invested in Karyopharm Therapeutics in 2014 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 8

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

19% more capital invested

Capital invested by funds: $587M → $701M (+$114M)

14% more funds holding

Funds holding: 71 → 81 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

19% less call options, than puts

Call options by funds: $1.34M | Put options by funds: $1.65M

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
2.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
19
Increased
29
Reduced
19
Closed
8
Calls
$1.34M
Puts
$1.65M
Net Calls
-$306K
Net Calls Change
-$90K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$32M
2
BFA
BlackRock Fund Advisors
California
+$16.8M
3
Franklin Resources
Franklin Resources
California
+$8.81M
4
State Street
State Street
Massachusetts
+$4.07M
5
UBS AM
UBS AM
Illinois
+$3.95M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$10.4M
2
BA
BlackRock Advisors
Delaware
-$4.43M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$4.23M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$3.69M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
76
Tower Research Capital (TRC)
New York
$4K -$34.6K -61 -90%
NFG
77
Next Financial Group
Texas
$4K – – –
CFA
78
CT Financial Advisors
Pennsylvania
$3.74K +$3.98K +7 New
RFC
79
Russell Frank Company
Washington
$3K – – –
Bank of Montreal
80
Bank of Montreal
Ontario, Canada
$3K +$2.84K +5 New
Manulife (Manufacturers Life Insurance)
81
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$309 -$7.95K -14 -2%
Balyasny Asset Management
82
Balyasny Asset Management
Illinois
– -$3.48M -6,642 Closed
EAM
83
EverPoint Asset Management
Connecticut
– -$2.27M -4,323 Closed
Point72 Asset Management
84
Point72 Asset Management
Connecticut
– -$1.38M -2,627 Closed
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
– -$210K -400 Closed
PAM
86
Panagora Asset Management
Massachusetts
– -$32K -62 Closed
BNP Paribas Financial Markets
87
BNP Paribas Financial Markets
France
– -$30.6K -58 Closed
SSG
88
Summit Securities Group
New York
– -$1K -2 Closed
Ameriprise
89
Ameriprise
Minnesota
– -$1K -1 Closed
1 2 3
4

KPTI Hedge Fund Activity: Q4 2014 in Review

81 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2014, worth a combined $701M — up 19% from $587M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KPTI positions and 8 closed out — a net gain of 11 holders — while 29 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $32M. The largest seller was PFM Health Sciences, cutting an estimated $10.4M.

  • 81 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2014, up from 71 in Q3 2014.
  • Funds reported $701M of Karyopharm Therapeutics stock for Q4 2014, up 19% quarter-over-quarter.
  • 19 funds opened new Karyopharm Therapeutics positions in Q4 2014 and 8 closed out, a net change of +11 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $32M added.
  • The largest Karyopharm Therapeutics seller in Q4 2014 was PFM Health Sciences, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2014.